Short-term prognosis in primary and secondary major depression

BackgroundThe features of adolescents who had taken an overdose were assessed to determine the focus for a treatment trial.MethodOverdose cases were compared with psychiatric and community controls who had not taken an overdose in respect of mental disorders and family background.ResultsOverdose cases had high rates of major depression, but most of them recovered from depression within six weeks of the overdose. There was a specific association between taking an overdose and family dysfunction.ConclusionsFamily dysfunction could be a useful focus in a clinical trial of the aftercare of adolescents who have taken an overdose.

Download Full-text

Cost-effectiveness of selective serotonin reuptake inhibitors and routine specialist care with and without cognitive–behavioural therapy in adolescents with major depression

The British Journal of Psychiatry ◽

10.1192/bjp.bp.107.038984 ◽

2007 ◽

Vol 191 (6) ◽

pp. 521-527 ◽

Cited By ~ 53

Author(s):

Sarah Byford ◽

Barbara Barrett ◽

Chris Roberts ◽

Paul Wilkinson ◽

Bernadka Dubicka ◽

...

Keyword(s):

Cost Effectiveness ◽

Major Depression ◽

Cognitive Behavioural Therapy ◽

Serotonin Reuptake ◽

Selective Serotonin Reuptake Inhibitors ◽

Clinical Care ◽

Cost Effective ◽

Behavioural Therapy ◽

Short Term ◽

Cognitive Behavioural

BackgroundMajor depression is an important and costly problem among adolescents, yet evidence to support the provision of cost-effective treatments is lacking.AimsTo assess the short-term cost-effectiveness of combined selective serotonin reuptake inhibitors (SSRIs) and cognitive–behavioural therapy (CBT) together with clinical care compared with SSRIs and clinical care alone in adolescents with major depression.MethodPragmatic randomised controlled trial in the UK. Outcomes and costs were assessed at baseline, 12 and 28 weeks.ResultsThe trial comprised 208 adolescents, aged 11–17 years, with major or probable major depression who had not responded to a brief initial psychosocial intervention. There were no significant differences in outcome between the groups with and without CBT. Costs were higher in the group with CBT, although not significantly so (P=0.057). Cost-effectiveness analysis and exploration of the associated uncertainty suggest there is less than a 30% probability that CBT plus SSRIs is more cost-effective than SSRIs alone.ConclusionsA combination of CBT plus SSRIs is not more cost-effective in the short-term than SSRIs alone for treating adolescents with major depression in receipt of routine specialist clinical care.

Download Full-text

P01-92 - Early changes are associated with late changes of BDNF serum levels in inpatients with major depression during short-term antidepressant treatment

European Psychiatry ◽

10.1016/s0924-9338(10)70311-4 ◽

2010 ◽

Vol 25 ◽

pp. 313

Author(s):

K.F. Schlicht ◽

S. Wagner ◽

D. Peetz ◽

L. Borysenko ◽

D. Krannich ◽

...

Keyword(s):

Major Depression ◽

Antidepressant Treatment ◽

Serum Levels ◽

Short Term

Download Full-text

Natural Course and Placebo Response in Short-Term, Placebo-Controlled Studies in Major Depression: A Meta-Analysis of Published and Non-published Studies

Pharmacopsychiatry ◽

10.1055/s-2004-815472 ◽

2004 ◽

Vol 37 (1) ◽

pp. 32-36 ◽

Cited By ~ 10

Keyword(s):

Major Depression ◽

Meta Analysis ◽

Placebo Response ◽

Natural Course ◽

Short Term

Download Full-text

Short-Term Outcome of Major Depression: I. Comorbidity and Severity at Presentation as Predictors of Persistent Disorder

Journal of the American Academy of Child & Adolescent Psychiatry ◽

10.1097/00004583-199702000-00008 ◽

1997 ◽

Vol 36 (2) ◽

pp. 179-187 ◽

Cited By ~ 62

Author(s):

IAN M. GOODYER ◽

JOE HERBERT ◽

SANDRA M. SECHER ◽

JOSEPHINE PEARSON

Keyword(s):

Major Depression ◽

Short Term ◽

Term Outcome ◽

Short Term Outcome

Download Full-text

Cognitive symptoms in mayor depression: A study with vortioxetina

European Psychiatry ◽

10.1016/j.eurpsy.2017.01.742 ◽

2017 ◽

Vol 41 (S1) ◽

pp. S538-S538

Author(s):

O. Porta Olivares ◽

M. Juncal Ruiz ◽

B. Fernández Abascal Puente ◽

M. Gómez Revuelta ◽

M. Pérez Herrera ◽

...

Keyword(s):

Major Depression ◽

Short Term Memory ◽

Cognitive Symptoms ◽

Therapeutic Tool ◽

Short Term ◽

Symptoms Of Depression ◽

Hearing Test ◽

Previously Treated ◽

Competing Interest ◽

Significant Factors

IntroductionThe major depression is associated with decreased cognitive functions in a range of areas, including attention, memory and executive functions. The cognitive symptoms of depression can have a profound effect on the ability of patients to keep out the tasks of daily living, and are significant factors that affect the ability to function both interpersonal and occupational level.AimsVortioxetina have a multimodal action acting on various serotonin receptors in addition to inhibiting serotonin reuptake. Vortioxetina, is a new therapeutic tool seems to have shown efficacy in the treatment of cognitive symptoms of depression.MethodsTo evaluate this action we have evaluated the cognitive decline in patients with major depression before receiving treatment vortioxetina (whether state or not previously treated with other antidepressants) and at 2, 6 and 12 months after starting treatment with the drug. For that, we’ve used the Verbal Hearing Test King (RAVLT), which evaluates the auditory verbal short-term memory, the learning rate, the retention of information, and the differences between learning and recovery, and testing Digit substitution by symbols (DSST) that perform quick detection of brain dysfunctions by a conventional task.ResultsThe results of this study are still under analysis.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Download Full-text